Abstract

Research on the neurobiology of cancer, which lies at the border of neuroscience and oncology, has elucidated the mechanisms and pathways that enable the nervous system to modulate processes associated with cancer initiation and progression. This research has also shown that several drugs which modulate interactions between the nervous system and the tumor micro- and macroenvironments significantly reduced the progression of cancer in animal models. Encouraging results were also provided by prospective clinical trials investigating the effect of drugs that reduce adrenergic signaling on the course of cancer in oncological patients. Moreover, it has been shown that reducing adrenergic signaling might also reduce the incidence of cancer in animal models, as well as in humans. However, even if many experimental and clinical findings have confirmed the preventive and therapeutic potential of drugs that reduce the stimulatory effect of the nervous system on processes related to cancer initiation and progression, several questions remain unanswered. Therefore, the aim of this review is to critically evaluate the efficiency of these drugs and to discuss questions that need to be answered before their introduction into conventional cancer treatment and prevention.

Highlights

  • IntroductionPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations

  • There are several reasons that propranolol is the most often used β blocker in the investigation of neurobiology of cancer: (a) it was the first β blocker effectively used in the treatment of coronary artery disease and hypertension and has been used in clinical practice for a long time [41]; (b) its pharmacological properties have been described in detail [42]; (c) there have been several retrospective studies involving patients treated with propranolol that have investigated the effect of β blockers on cancer incidence and progression [43,44,45,46,47,48,49,50,51]; (d) propranolol is readily available, inexpensive, and applicable in animal experiments; (e) as a clinically approved drug, off-label propranolol use by cancer patients in clinical trials is highly likely to be considered acceptable by the approving authorities of these studies

  • The neurobiology of cancer has revealed new mechanisms and pathways participating in cancer initiation and progression

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Data accumulated in the last few decades have clearly shown that the nervous system plays a significant role in cancer initiation and progression These data are based on combined neuroscientific and oncological research that has created the basis for a new scientific concept, the so-called neurobiology of cancer [1]. Experimental and clinical studies have shown that drugs that modulate the transmission of signals between the nervous system and the tumor micro- and macroenvironments efficiently suppress cancer initiation and progression. These data indicate that pharmacological approaches based on findings of the neurobiology of cancer might be utilized in the treatment of cancer patients as well as in cancer prevention for individuals with an increased cancer risk. The following sections are focused on drugs that are approved for the treatment of non-cancerous diseases, as well as experimental drugs, that, via modulation of nervous system-related signaling and functions, could affect carcinogenesis and cancer growth

Propranolol
Propranolol and Cancer Incidence
Propranolol and Cancer
Propranolol and Cancer Progression
Propranolol and Efficiency of Conventional Anti-Cancer Treatment
Dosage
The Issues Related to Propranolol Usage in Oncology
Drugs Reducing Density or Activity of Nerves Innervating Cancer Tissue
Drugs Reducing Nerve Growth Factor-Related Signaling
Botulotoxin
Electroceuticals
Local Anesthetics
Drugs Interfering with Cancer Effects on the Brain
Aspirin
Metformin
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.